Olaparib Tablets Maintenance Monotherapy Ovarian Cancer patients after Complete or Partial Response to Platinum Chemotherapy

Trial Identifier: D0816C00016
Sponsor: AstraZeneca
NCTID:: NCT03534453
Start Date: May 2018
Primary Completion Date: October 2023
Study Completion Date: October 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China, 100142
China Changsha, China, 410013
China Chengdu, China, 610041
China Chongqing, China, 400030
China ChongQing, China, 400038
China Hangzhou, China, 310006
China Hangzhou, China, 310022
China Harbin, China, 150081
China Hefei, China, 230031
China Jinan, China, 250012
China shanghai, China, 200011
China Shanghai, China, 200032
China Shanghai, China, 200080
China Shenyang, China, 110016
China Tianjin, China
China Tianjin, China, 300060
China Wuhan, China, 430079
China Wuhan, China, CN-430030
China Xian, China, 710061
China Zhengzhou, China, 450008
India Vellore, India, 632004
Malaysia Johor Bahru, Malaysia, 81100
Malaysia Kuala Lumpur, Malaysia, 59100
Malaysia Kuala Lumpur, Malaysia
Malaysia Kuching, Malaysia, 93586
Malaysia Putrajaya, Malaysia